Current and future therapeutic options for the management of gout.
The incidence of gout and the clinical manifestation of hyperuricemia continue to rise. In addition to painful acute attacks, chronic gout can lead to the development of crystal arthropathy, tophi, and renal lithiasis, coincidental with declines in quality of life. As a greater appreciation for the associations between hyperuricemia, gout, and certain comorbidities, such as renal impairment and cardiovascular diseases, grows, so does the search for new therapeutic options to both alleviate the painful symptoms of acute gout attacks and reduce the underlying hyperuricemia. This manuscript reviews the pathophysiology of hyperuricemia and gout, and associated comorbidities, and then discusses traditional therapeutic options, newly available agents, and future targets for pharmacologic management.
Whelton
Andrew
A
Universal Clinical Research Center, Inc., Hunt Valley, MD, USA. huntvalley@aol.com
D000818:Animals; D016503:Drug Delivery Systems; D015195:Drug Design; D006073:Gout / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D033461:Hyperuricemia / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D011788:Quality of Life; D014527:Uric Acid / Q000378:metabolism; D014528:Uricosuric Agents / Q000627:therapeutic use
D014528:Uricosuric Agents; D014527:Uric Acid